Indaptus Therapeutics Executive Compensation Details
Ticker: INDP · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1857044
| Field | Detail |
|---|---|
| Company | Indaptus Therapeutics, INC. (INDP) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, stock-awards, sec-filing
TL;DR
Indaptus Therapeutics DEF 14A out: exec pay details for 2024, stock awards in focus.
AI Summary
Indaptus Therapeutics, Inc. filed a DEF 14A on April 28, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on stock and option awards, with specific data points related to the fair value of these awards for both PEO (Principal Executive Officer) and Non-PEO members. The company, formerly known as Intec Parent Inc., is based in New York.
Why It Matters
This filing provides transparency into how Indaptus Therapeutics compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the specifics of executive compensation can sometimes signal underlying company performance or governance concerns.
Key Numbers
- 2024 — Fiscal Year (Executive compensation reporting period)
- 2023 — Fiscal Year (Prior year data for comparison)
- 2022 — Fiscal Year (Prior year data for comparison)
Key Players & Entities
- Indaptus Therapeutics, Inc. (company) — Filer
- Intec Parent Inc. (company) — Former Company Name
- 2024-12-31 (date) — Fiscal Year End
- 20250428 (date) — Filing Date
FAQ
What is the total compensation for the Principal Executive Officer (PEO) in 2024?
The filing provides data points for PEO members regarding stock and option awards, including fair value calculations, but the total compensation figure is not explicitly stated in the provided excerpt.
What was the company's former name?
The company's former name was Intec Parent Inc., with a name change date of April 14, 2021.
When was this DEF 14A filing submitted?
This filing was submitted on April 28, 2025.
What is the primary business of Indaptus Therapeutics, Inc.?
Indaptus Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What specific compensation elements are detailed for 2024?
The filing details deductions for amounts reported under stock awards and option awards, as well as increases based on ASC Seven One Eight fair value of awards granted during the fiscal year that remain unvested.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Indaptus Therapeutics, Inc. (INDP).